Transforming Women’s Health
and Fertility Care


AblaCare develops an innovative solution for Polycystic Ovary Syndrome (PCOS) related infertility, designed to provide patients with a more natural and less medicalised pregnancy experience.

AblaCare aims to restore ovulation in PCOS patients through a simple, one-time, durable, minimally invasive treatment. AblaCare's procedure is done transvaginally, under ultrasound guidance, and does not require general anesthesia. The technique can be performed in the clinic setting using the same minimally invasive access commonly used by fertility physicians for IVF.


10/07 : AblaCare Announces Series A Financing of €10 Million by Sofinnova Partners for Innovative Infertility Treatment and Appoints Jodie Fam as CEO


Jodie Fam - CEO
Jodie brings more than 20 years of medical device experience leading early stage medical device product development, market access and commercialization for major medtech companies and several venture-backed startups. She has been instrumental in bringing a number of early-stage, paradigm-shifting medical technologies to market in diverse and competitive environments. Jodie has held top management roles at Concentric Medical (acquired by Stryker), Medina Medical (acquired by Medtronic), Route 92 Medical and CardioKinetix, as well as senior sales and marketing positions with Johnson & Johnson, Guidant Corporation and Mallinckrodt Medical.
Andrew M. Weiss, Chairman

Want to LEARN more?

Over 10% of women worldwide are affected by PolyCystic Ovary Syndrome, a leading cause of female infertility.

At AblaCare, we are developing an innovative treatment for PCOS infertility which would be less risky and less invasive than current options.

Contact Us